US Peptide Science Research Team
October 23, 2026
Retatrutide is a novel triple-receptor agonist that simultaneously activates glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon receptors. This multi-target approach distinguishes retatrutide from existing GLP-1 monotherapy agents. The triple-agonist mechanism is hypothesized to produce synergistic effects on appetite regulation, energy expenditure, and glucose metabolism—though the relative contribution of each receptor pathway to clinical outcomes remains an area of ongoing investigation.
The TRIUMPH clinical trial program represents a comprehensive Phase 3 registration effort conducted across multiple populations. This article synthesizes efficacy and safety data from TRIUMPH-1 and TRIUMPH-2, the primary weight-management basket trials that enrolled over 3,000 participants combined.
eli.lilly.com published the primary results of TRIUMPH-1, a Phase 3 randomized, double-blind trial that enrolled 2,339 adults with obesity. The study excluded participants with type 2 diabetes, allowing assessment of retatrutide's weight-reduction efficacy in a population without existing glycemic dysfunction. Participants received once-weekly subcutaneous injections of retatrutide at doses of 4 mg, 9 mg, or 12 mg, or placebo, for 80 weeks.
The trial incorporated two nested basket populations: 574 participants with concurrent knee osteoarthritis and 243 with obstructive sleep apnea, enabling simultaneous evaluation of retatrutide's effects on these obesity-related comorbidities.
The primary efficacy endpoint—percent change in body weight at 80 weeks—showed clear dose-response relationships:
Source research
Referenced literature: PubMed Central / The Lancet. No direct link is attached to this article.
Estimated treatment differences for the 9 mg and 12 mg doses versus placebo were −19.8 and −21.0 percentage points, respectively (P<0.001 for both). These findings represent substantial weight reduction relative to the modest placebo effect, supporting the hypothesis that retatrutide's triple-receptor agonism produces clinically meaningful weight loss.
Among the 574 participants with knee osteoarthritis, retatrutide reduced Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores in a dose-dependent manner, according to medical.lilly.com:
In the 243 participants with obstructive sleep apnea, retatrutide reduced the apnea-hypopnea index (events per hour) in dose-dependent fashion:
These secondary endpoints suggest that weight reduction alone does not fully explain improvements in sleep apnea severity, implying direct effects of GIP/GLP-1/glucagon receptor agonism on respiratory physiology or airway mechanics.
thelancet.com published TRIUMPH-2 results in 2026, evaluating retatrutide in 1,152 adults with concurrent obesity (mean baseline BMI 38.2 kg/m²) and type 2 diabetes (mean baseline HbA₁c 7.71%). Participants were on stable glucose-lowering therapy for at least 90 days prior to randomization, including diet/exercise alone or up to three oral agents. The trial design mirrored TRIUMPH-1: 80 weeks of once-weekly subcutaneous retatrutide (4 mg, 9 mg, or 12 mg) versus placebo.
Mean percent change in body weight at week 80 (treatment regimen estimand):
Estimated treatment differences versus placebo were −6.9% (95% CI −8.7 to −5.1) for 4 mg, −11.8% (−13.7 to −9.8) for 9 mg, and −13.8% (−15.8 to −11.8) for 12 mg (p<0.0001 for all). While absolute weight loss in TRIUMPH-2 was numerically lower than in TRIUMPH-1, the presence of type 2 diabetes and higher baseline BMI in the population may explain this difference. Notably, weight loss in the retatrutide groups was accompanied by improvements in glycemic control, consistent with retatrutide's GLP-1 receptor agonism.
Both trials identified gastrointestinal adverse events as the most frequently reported category, with dose-dependent patterns.
According to eli.lilly.com, gastrointestinal adverse events in TRIUMPH-1 included:
Additional adverse events included dysesthesia (5.1% at 4 mg, 12.3% at 9 mg, 12.5% at 12 mg vs. 0.9% placebo) and urinary tract infections (7.5–8.8% across retatrutide doses vs. 5.3% placebo). Discontinuation rates due to adverse events were 4.1% (4 mg), 6.9% (9 mg), and 11.3% (12 mg), compared with 4.9% for placebo.
In TRIUMPH-2, gastrointestinal adverse events showed clear dose-response relationships, per thelancet.com:
Other notable adverse events included:
Permanent treatment discontinuation due to adverse events or death occurred in 4% (4 mg), 12% (9 mg), 8% (12 mg), and 5% (placebo). Four deaths were reported across the trial arms (2 in 4 mg, 3 in 9 mg, 1 in 12 mg, 1 in placebo); investigators deemed all deaths unrelated to study intervention.
Both TRIUMPH-1 and TRIUMPH-2 demonstrated dose-dependent efficacy: higher doses of retatrutide produced greater weight loss, pain reduction in osteoarthritis, and apnea-hypopnea index reduction. However, higher doses also correlated with increased adverse event rates, particularly gastrointestinal symptoms and treatment discontinuation.
The 4 mg dose, which required only one up-titration step, produced approximately 19% weight reduction in TRIUMPH-1 and 11.9% in TRIUMPH-2. The 12 mg dose achieved up to 28.3% weight reduction in TRIUMPH-1 but was associated with higher discontinuation rates. This risk-benefit profile suggests that individual dose selection may require balancing maximal efficacy against tolerability.
The TRIUMPH trial program represents the first comprehensive Phase 3 evaluation of a triple-receptor agonist for weight management. The magnitude of weight reduction—particularly the 25% observed with 12 mg retatrutide in TRIUMPH-1—exceeds that reported for GLP-1 monotherapy agents in comparable populations, though direct head-to-head comparisons are not available from these trials.
The secondary outcomes in nested populations (obstructive sleep apnea and knee osteoarthritis) suggest that retatrutide may produce benefits beyond weight reduction alone. However, the extent to which these improvements are independent of weight loss versus mediated through weight reduction requires further mechanistic investigation.
Researchers investigating weight loss pharmacology, obesity-related comorbidities, or multi-target receptor agonism may find these data relevant to understanding how triple-agonist mechanisms compare to existing therapeutic approaches. The gastrointestinal safety profile is consistent with other GLP-1 receptor agonists, though the dysesthesia and hypotension signals warrant monitoring in real-world use.
Both TRIUMPH trials employed rigorous Phase 3 methodology, including randomization, blinding, and pre-specified statistical analysis plans. However, the 80-week follow-up period does not address long-term durability of weight loss beyond the active treatment phase. Additionally, the trials enrolled primarily in high-income countries, potentially limiting generalizability to other populations. The gastrointestinal adverse event profile may influence real-world adherence, though TRIUMPH-2 reported 84% study completion, suggesting tolerability was manageable for most participants.
The TRIUMPH-1 and TRIUMPH-2 Phase 3 trials provide robust evidence that retatrutide, a triple-receptor agonist of GIP, GLP-1, and glucagon receptors, produces dose-dependent weight reduction in adults with obesity, with or without type 2 diabetes. The 9 mg and 12 mg doses achieved clinically meaningful weight loss (23.7–25.0% in TRIUMPH-1; 16.8–18.8% in TRIUMPH-2) compared to placebo. Secondary outcomes in participants with obstructive sleep apnea and knee osteoarthritis demonstrated improvements in disease-specific metrics. The safety profile was dominated by gastrointestinal adverse events, with higher rates at higher doses. These findings position retatrutide as a potentially significant pharmacological option for weight management research and establish the triple-agonist mechanism as a viable approach to obesity treatment.